Skip to main content

Advertisement

SpringerLink
Log in

Pediatric myelodysplastic syndromes

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

A new classification of myelodysplastic and myeloproliferative diseases in childhood has greatly facilitated the diagnosis of these uncommon disorders. Because hematopoietic stem cell transplantation (HSCT) can cure more than half of the affected children, palliative treatment strategies often applied in adult myelodysplastic syndrome (MDS) are of little importance in pediatric MDS. Unraveling some of the underlying genetic factors predisposing to MDS at a young age may give important insights into leukemogenesis in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Edited by Jaffe EJ, Harris NL, Stein H, Vardiman JW. Lyon: International Agency for Research on Cancer; 2001.

  2. Kardos G, Baumann I, Passmore SJ, et al.: Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003, 102:1997–2003. This paper reviews clinical courses observed in a large cohort of children with refractory cytopenia.

    Article  PubMed  CAS  Google Scholar 

  3. Hasle H, Niemeyer CM, Chessells JM, et al.: A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003, 17:277–282. This paper summarizes the present classification scheme employed in pediatric myelodysplastic syndrome.

    Article  PubMed  CAS  Google Scholar 

  4. Passmore SJ, Chessells JM, Kempski H, et al.: Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003, 121:758–767. This paper describes a large cohort of pediatric patients with myelodysplastic syndrome.

    Article  PubMed  Google Scholar 

  5. Hasle H, Baumann I, Bergstrasser E, et al.: The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004, 18:2008–2014.

    Article  PubMed  CAS  Google Scholar 

  6. Saunthararajah Y, Nakamura R, Nam JM, et al.: HLADR15 (DR2) is over-represented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570–1574.

    PubMed  CAS  Google Scholar 

  7. Steensma DP, Dispenzieri A, Moore SB, et al.:Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003, 101:2156–2158.

    Article  PubMed  CAS  Google Scholar 

  8. Peters AMJ, Baumann I, Strahm B: Immunosuppressive therapy for children with refractory anemia [abstract]. Bone Marrow Transplant 2003, 31:S183.

    Article  Google Scholar 

  9. Hicsonmez G, Tuncer AM, Sayli T, et al.: High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes. Hematol Pathol 1995, 9:185–193.

    PubMed  CAS  Google Scholar 

  10. Webb DK, Passmore SJ, Hann IM, et al.: Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990 to 1999. Br J Haematol 2002, 117:33–39.

    Article  PubMed  Google Scholar 

  11. Woods WG, Barnard DR, Alonzo TA, et al.: Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children’s Cancer Group. J Clin Oncol 2002, 20:434–440.

    Article  PubMed  Google Scholar 

  12. Sasaki H, Manabe A, Kojima S, et al.: Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001, 15:1713–1720.

    PubMed  CAS  Google Scholar 

  13. Hasle H, Kerndrup G, Yssing M, et al.: Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996, 10:1269–1273.

    PubMed  CAS  Google Scholar 

  14. Chan GC, Wang WC, Raimondi SC, et al.: Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low-blast count. Leukemia 1997, 11:206–211.

    Article  PubMed  CAS  Google Scholar 

  15. Niemeyer CM, Zecca M, Korthoff E, et al.: Allogeneic stem cell transplantation for children with advanced primary MDS: results from the EWOG-MDS study group employing a pretransplant preparative regimen with busulfan, cyclophosphamide, and melphalan [abstract]. Blood 2004, 104:632a.

    Google Scholar 

  16. Yusuf U, Frangoul HA, Gooley TA, et al.: Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004, 33:805–814.

    Article  PubMed  CAS  Google Scholar 

  17. Leahey AM, Friedman DL, Bunin NJ: Bone marrow transplantation in pediatric patients with therapyrelated myelodysplasia and leukemia. Bone Marrow Transplant 1999, 23:21–25.

    Article  PubMed  CAS  Google Scholar 

  18. Deeg HJ, Storer B, Slattery JT, et al.: Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201–1207.

    Article  PubMed  CAS  Google Scholar 

  19. Peters C, Matthes-Martin S, Fritsch G: Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 1999, 13:2070–2078.

    Article  PubMed  CAS  Google Scholar 

  20. Locatelli F, Zecca M, Duffner U, et al.: Busulfan, cyclophosphamide, and melphalan as pretransplant conditioning regimen for children with myelodysplasia (MDS) and juvenile myelomonocytic leukaemia (JMML). Interim analysis of the EWOGMDS/ EBMT prospective study. Leukemia 2002, 14:971.

    Google Scholar 

  21. List AF, Vardiman J, Issa JP, Dewitte TM: Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2004, 297–317.

  22. Barnard DR, Lange B, Alonzo TA, et al.: Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood 2002, 100:427–434.

    Article  PubMed  CAS  Google Scholar 

  23. Yakoub-Agha I, de La SP, Ribaud P, et al.: Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000, 18:963–971.

    PubMed  CAS  Google Scholar 

  24. Hale GA, Heslop HE, Bowman LC, et al.: Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant 1999, 24:735–739.

    Article  PubMed  CAS  Google Scholar 

  25. de Witte T, Hermans J, Vossen J, et al.: Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000, 110:620–630.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Mathildenstrasse 1, 79106, Freiburg, Germany

    Charlotte Marie Niemeyer MD

Authors
  1. Charlotte Marie Niemeyer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Peter Kratz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henrik Hasle MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niemeyer, C.M., Kratz, C.P. & Hasle, H. Pediatric myelodysplastic syndromes. Curr. Treat. Options in Oncol. 6, 209–214 (2005). https://doi.org/10.1007/s11864-005-0004-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0004-3

Keywords

Search

Navigation